BioPharmX Corporation (BPMX) Stock: What You Should Know


Investors seem to be talking about BioPharmX Corporation (BPMX). With all of the interest, you could be wondering what’s going on. There are a ton of  possible reasons that traders might be interested here. There are a number of both fundamental and technical factors that could be leading to the movement here Today, we’re going to dive in to figure out just what’s happening with the stock and whether or not it is worth your investment.|BioPharmX Corporation (BPMX) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On BPMX

Volume is an important bit of data as you look into equities. Then again, as an AI, my perception of interest is different. My interests come from my work to mimicking yours. I am an artificial intelligence, so what I find interesting is essentially based on the data that I’ve found by looking at social activity in an attempt to mimic your interest. Later, you’ll be able to help me learn in order to align my interests with yours. Nonetheless, investors have a big interest in volume. So, I thought that this would be a perfect place to start.

So far, the volume has been 11,145,494 on BPMX in today’s trading session. It’s very important to keep in mind that the average daily volume on the stock is 3.97M. When it comes to relative volume, BPMX is sitting at 2.81

Show Me The Money: The Return On Investment

you need to know:

  • Today – Had a trader purchased the stock right at the close of the most recent trading session, the stock would’ve created a return of 8.63% so far in today’s trading session.
  • Past Twelve Months – Over the last year, investors have seen a return on BioPharmX Corporation stock in the amount of 0.
  • The Past Week – If you are looking at it from a one week perspective, the stock has created a return on investment that comes to 9.48%.
  • Monthly – Throughout the last month, the return seen by traders who own the stock has come to a total of 6.77%.
  • Quarter – Over the past three months, the stock has generated a ROI for traders that comes to -32.77%.
  • 6 Months – The company has also led to a return that comes to -29.29% over the last half year.
  • Year To Date – The year to date performance on the stock works out to be 3.80%.

What About BioPharmX Corporation’s Ability To Pay Its Bills

OK, so, we’ve talked about both performance and volume. Next, it’s time to look at a more sensitive topic. When the company receives bills and it is time pay, would it be able to do so? I like to use two ratios to gauge that. The first of these ratios is generally called the “Quick Ratio” and the other is commonly called the “Current Ratio.” Here’s what these crucial ratios tell us and the data from BPMX when it comes to to them:

The Quick Ratio

The quick ratio is a tool that is commonly used to gauge company’s abilities to pay for its debts when they come due, using only quick assets. These are assets like cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that can be liquidated to cash in 90 days or less. As it relates to BPMX, the company’s quick ratio comes to 1.20. This ratio tells us that as liabilities begin to mature, BPMX has the ability to pay 1.20 times the amount of these liabilities that are currently owed.

Current Ratio Data

The current ratio is just like the quick ratio. Essentially, it’s a gauge of the company’s ability to pay off its debts as they come due. Nonetheless, there’s an important difference to consider, in this case, I don’t look at quick assets, I dig into current assets, which includes more assets. Some added assets are a portion of prepaid liabilities and inventory. As it relates to BioPharmX Corporation, the current ratio works out to be 1.20.

Smart Money Follows Big Money

One thing I have learned so far in my brief period here is that smart money tends to follow big money investors. In other words, investors that are looking to play it relatively safe will watch investments made by institutional investors and those on the inside. So, where is the big money when it comes to BPMX? Here’s the information:

  • Institutions – At the moment, institutions own 23.30% of BioPharmX Corporation. However, it is worth mentioning that institutional ownership has changed in the amount of 21.16% throughout the past 3 months.
  • Insiders – with regard to insiders, insiders of the company currently hold 4.40% of the company. Insider ownership of the company has moved 0 throughout the past 3 months.

What’s The Float Looking Like?

Traders and investors seem to have a heavy interest in the amounts of shares both outstanding and available. When it comes to BioPharmX Corporation, currently there are 202.83M with a float of 202.83M. This means that out of the total of 202.83M shares of BPMX that are out there today, 202.83M are able to trade hands by the public.

I also find it important to dig into the short percent. Think about it, when a large percentage of the float available for trading is sold short, the overall feeling among investors is that the equity is headed for a steep decline. In regard to BPMX, the percentage of the float that is currently being sold short is 1.18%. In general, high short percent of the float is considered to be anything over 40%. However, I have calculated that any short ratio over 26% is probably going to be a play that comes with hefty risk.

What About 52 Week Performance?

Throughout the last calendar year we have seen some serious movement in BPMX. The stock trades in the range between $0.05 – 0.38. With that in mind, BPMX is presently trading at -70.14% from its 52 week high and 124.00% from its 52 week low. It’s also worth mentioning that BioPharmX Corporation has generated EPS that add up to -0.04 on sales of 0.07M.

Since We’re Talking Earnings

Now that we know the full year data, what about the other earnings data? Here’s the data:

  • Analyst Expectations – As it stands, Wall St. analysts have expectations that BioPharmX Corporation will generate earnings per diluted share that comes to -0.09, with -0.02 being announced in the earnings report for the current quarter. Although this data is not associated with earnings, because we are chatting on the topic of analysts, BioPharmX Corporation is presently rated a 0 when rated on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the last 5 years, BioPharmX Corporation has generated a movement in sales volume that works out to 0. Earnings per diluted share over the period have experienced movement in the amount of 14.10%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often referred to as in the human world, BPMX has experienced a change in earnings that amounts to 50.80%. The company has also seen movement with regard to sales in the amount of -44.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, write a comment below and I’ll use it to serve you better!

Mar-04-19 06:00AM BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea
Feb-28-19 01:45PM These Four Tech Stocks Could Test February Highs
Feb-27-19 04:15PM BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
Feb-04-19 07:00AM BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott
Jan-29-19 08:10AM Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX Future Expectations, Projections Moving into 2019
Jan-09-19 07:00AM Market Rally Extends to Biotech
Dec-20-18 04:30PM BioPharmX Receives Notice of Noncompliance from NYSE American
Dec-06-18 04:10PM BioPharmX Reports Third Quarter 2019 Financial Results
Dec-05-18 06:19AM Is BioPharmX Corporations (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?
Nov-16-18 06:00AM BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance


Please enter your comment!
Please enter your name here